Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years

NCT07860216 is registered in ClinicalTrials.gov with Beijing BeneWill Technology Development Co., Ltd as lead sponsor.

NCT NCT07860216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07860216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years
Lead sponsor
Beijing BeneWill Technology Development Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
August 21, 2026
Completion date
December 31, 2028
Enrollment
25,000 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

assessing the effectiveness of vaccines in preventing adult rsv-caused lower respiratory tract disease (lrtd)